prikaz prve stranice dokumenta Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)
  Preuzmi
PDF 705.27 KB
Znanstveni rad - Izvorni znanstveni rad
Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)
Medicina, 60 (2024), 3; 430. https://doi.org/10.3390/medicina60030430
Hude Dragičević, Ida; Bašić-Kinda, Sandra; Markotić, Helena; Morić-Perić, Martina; Dujmović, Dino; Radman, Ivo; Dreta, Barbara; Dotlić, Snježana; Ilić, Ivana; Galunić Bilić, Lea; Dobrenić, Margareta; Kralik, Marko; Aurer, Igor

Citirajte ovaj rad

Hude Dragičević, I., Bašić Kinda, S., Markotić, H., Morić Perić, M., Dujmović, D., Radman, I. ... Aurer, I. (2024). Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP). Medicina, 60. (3). doi: 10.3390/medicina60030430

Hude Dragičević, Ida, et al. "Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)." Medicina, vol. 60, br. 3, 2024. https://doi.org/10.3390/medicina60030430

Hude Dragičević, Ida, Sandra Bašić Kinda, Helena Markotić, Martina Morić Perić, Dino Dujmović, Ivo Radman, Barbara Dreta, et al. "Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)." Medicina 60, br. 3 (2024). https://doi.org/10.3390/medicina60030430

Hude Dragičević, I., et al. (2024) 'Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)', Medicina, 60(3). doi: 10.3390/medicina60030430

Hude Dragičević I, Bašić Kinda S, Markotić H, Morić Perić M, Dujmović D, Radman I, i sur.. Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP). Medicina [Internet]. 02.03.2024. [pristupljeno 12.11.2024.];60(3). doi: 10.3390/medicina60030430

I. Hude Dragičević, et al., "Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)", Medicina, vol. 60, br. 3, Ožujak 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:456124. [Citirano: 12.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:456124
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Reduced Corticosteroid Exposure Is Safe and Does Not Reduce Disease Control among Hodgkin Lymphoma Patients Treated with Escalated BEACOPP (eBEACOPP)
AutorIda Hude Dragičević
AutorSandra Bašić-Kinda
AutorHelena Markotić
AutorMartina Morić-Perić
AutorDino Dujmović
AutorIvo Radman
AutorBarbara Dreta
AutorSnježana Dotlić
AutorIvana Ilić
AutorLea Galunić Bilić
AutorMargareta Dobrenić
AutorMarko Kralik
AutorIgor Aurer
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA PATOLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Patologija
Sažetak (engleski)
Background and Objectives: eBEACOPP is the most effective chemotherapy regimen for younger patients with early unfavorable (EU) and advanced-stage (AS) Hodgkin lymphoma (HL), albeit with significant toxicities. The 14-day/cycle prednisone course contributes to side effects, including osteoarticular events like avascular bone necrosis (AVN). Our center has been using eBEACOPP since 2009 for AS and 2014 for EU patients. In 2016, we reduced prednisone treatment to 7–10 days to lessen AVN risk. We analyzed the effects of this approach. Materials and Methods: We retrospectively collected data on patients who received at least two cycles of eBEACOPP for first-line HL treatment. Results: A total of 162 patients (33 EU, 129 AS) were included. Their median age was 31 (range 19–59 years), and 88 were males. A total of 94 patients received full corticosteroid courses, and 68 received reduced corticosteroid courses. The overall response rate (ORR) was 98%. Different corticosteroid dosings had no significant effect on ORR, febrile neutropenia episodes, or hospital admissions. After a median follow-up (mFU) of 58 months, the 5yPFS for the entire cohort was 98% vs. 95% for the standard course vs. the short corticosteroids course, respectively (p = 0.37), while the 5yOS was 98% vs. 99% for the standard course vs. short corticosteroids course, respectively (p = 0.87). In AS patients intended to be treated with six eBEACOPP cycles, 5yPFS and 5yOS were 100% vs. 97% and 100% vs. 99% for standard vs. short corticosteroid courses, respectively (p = 0.56 and p = 0.17). In EU patients, 5yPFS was 97% (standard) vs. 95% (short) (p = 0.98) and 5yOS 100% vs. 93.3% (p = 0.87). Osteoarticular events were numerically lower in patients receiving the shorter prednisone course, both in the whole cohort and in the subgroup of patients treated with six cycles of eBEACOPP, but this difference failed to reach statistical significance. Conclusions: eBEACOPP provides excellent and durable first-line disease control. Shortening the corticosteroid course does not compromise efficacy, potentially reducing toxicity. However, longer follow-ups and larger studies are needed for confirmation.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaMedicina
Brojčani podacivol. 60, br. 3, 430
e-ISSN1648-9144
DOIhttps://doi.org/10.3390/medicina60030430
URN:NBNurn:nbn:hr:105:456124
Datum objave publikacije2024-03-02
URL dokumentahttps://www.mdpi.com/1648-9144/60/3/430
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-10-22 07:22:08